Compare Angi Inc (ANGI) vs Core Scientific Inc (CORZ) Price & Performance

ANGI trades at $4.41, down 3.92% with bearish technical signals and mixed fundamentals. Revenue declined to $1.03B in 2025, though net income improved to $44M. The stock appears undervalued with P/E of 14.81 and P/S of 0.19, but faces challenges with declining revenue trends and negative 2026 projections. Recent Q2 2026 earnings missed expectations with a $5.70 EPS loss versus $0.13 expected, while multiple law firms investigate potential securities violations.

Outlook remains challenging with revenue projected to decline to $993M in 2026 and net loss of $222M. The 59% upside to consensus price target of $7.00 offers potential reward, but risks include accelerating pro user churn, negative cash flow trends, and ongoing securities investigations. Analyst sentiment is cautious with 64% hold ratings amid fundamental deterioration.

CORZ trades at $21.30, up 9.57% in the last 24 hours, showing strong momentum despite a bearish technical signal. The stock faces fundamental challenges with a net income margin of -324.9% and negative EPS misses, but recent developments include a significant partnership with AMD for up to 2.5 gigawatts of data center capacity, potentially driving future revenue growth. Analyst sentiment remains overwhelmingly positive with 86% buy ratings and a consensus price target of $35.88.

The outlook for CORZ hinges on executing its AI infrastructure strategy, with the AMD deal offering substantial upside if successfully monetized. Key risks include persistent cash burn, competitive pressures, and reliance on long-term contracts. Investors should weigh the high growth potential against the current lack of profitability and volatile stock performance.